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Abstract: Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease 
  characterized by the accumulation of tau protein aggregates in the basal ganglia, brainstem and 
cerebral cortex leading to rapid disease progression and death. The neurofibrillary tangles that 
define the neuropathology of PSP are comprised of aggregated 4R tau and show a well-defined 
distribution. Classically, PSP is diagnosed by symptoms that include progressive gait disturbance, 
early falls, vertical ophthalmoparesis, akinetic-rigid features, prominent bulbar dysfunction and 
fronto-subcortical dementia. There are currently no effective therapies for the treatment of this 
rapidly degenerating and debilitating disease. Davunetide is a novel neuroprotective peptide that 
is thought to impact neuronal integrity and cell survival through the stabilization of microtubules. 
Preclinical activity in models of tauopathy has been translated to clinical studies, demonstrat-
ing pharmacologic activity that has supported further development. Davunetide’s efficacy and 
tolerability are being tested in a placebo-controlled study in PSP patients, making it the most 
advanced drug candidate in this indication. This review examines the disease characteristics 
of PSP, the rationale for treating PSP with davunetide and assesses some of the challenges of 
clinical trials in this patient population.
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Introduction
Progressive supranuclear palsy (PSP) is a rapidly progressing neurodegenerative 
  disease with a median survival after onset of symptoms of around 6 years.1,2 The 
classic clinical picture of PSP includes progressive gait disturbance, early falls, 
vertical ophthalmoparesis, akinetic-rigidity, prominent bulbar dysfunction and 
fronto-subcortical dementia.2–5 The loss of independent gait and the inability to stand 
unassisted occurs less than 3 years after disease onset6 with patients often wheel-
chair-bound by this time. With an estimated annual incidence of 5.3 per 100,000 in 
Europe and an age-adjusted prevalence of approximately 6.4 per 100,000, PSP is 
as common as motor-neuron disease or multiple system atrophy.7 However, this rate 
is almost certainly underestimated as many patients may be incorrectly diagnosed 
with Parkinson’s disease (PD), corticobasal degeneration (CBD) or Alzheimer’s 
disease (AD).
PSP is characterized by the pathological accumulation of hypherphosphorylated 
tau protein in the basal ganglia, brainstem and cerebral cortex. Severe neuronal loss 
in the substantia nigra, globus pallidus, subthalamic nucleus, midbrain, and pontine 
reticular formation accompanies neurofibrillary tangles that are composed of straight 
tau filaments.8 These neuronal tau deposits, and the coiled bodies and tufted astrocytes 
that are pathognomonic on PSP, are predominantly composed of “four-repeat (4R) tau”, 
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in distinction to Pick’s disease which is mostly “three-repeat 
(3R) tau” isoforms, and AD which is a mixture of 3R and 4R 
tau isoforms.9 In addition to the extensive and multifocal neu-
ropathological changes there are multiple neurotransmitter 
abnormalities, including dopamine, acetylcholine, gamma-
aminobutyric acid and the noradrenaline systems.10
The onset of symptoms is usually between the ages of 
50–70 years with both genders being nearly equally affected. 
Many patients report an insidious onset of disequilibrium 
and balance problems leading to postural instability, which 
is one of the early and most important clinical features. 
  Swallowing liquids and solids often becomes difficult as the 
disease progresses, leading to aspiration pneumonias which 
are the main cause of death in advanced PSP.
There are no approved treatments for PSP and the nega-
tive outcome of the majority of therapeutic studies precludes 
recommending an evidence-based standard therapy.11 Drug 
treatment usually starts with levodopa (L-DOPA) at doses 
as high as 1500 mg which may alleviate some of the bra-
dykinesia or rigidity, but rarely in a clinically meaningful 
way. Levodopa treatment may be accompanied by other 
therapies that are used for symptomatic improvement in PD.12 
However, none of these therapies provide effective control 
of symptoms, particularly in the early phase of the illness. 
PSP rapidly progresses over time and worsens dramatically 
within 1–3 years after symptom onset.6 Dopaminergic drug 
responses deteriorate and the need for alternative approaches 
increases.
In the absence of an identified biological marker for PSP 
pathology, early diagnosis and intervention before symptoms 
develop is not possible at this time. Secondary prevention 
to slow down, stop, or even reverse neuronal death after 
diagnosis would be a significant advance for the scientific 
and medical community.3
Until the recent publication of the Neuroprotection and 
Natural History in Parkinson Plus Syndromes (NNIPPS) 
trial, large scale controlled studies in patients with PSP had 
not been conducted. Although the NNIPPS trial2 has pro-
vided useful insights into atypical Parkinsonian disorders, it 
failed to detect an effect of riluzole on disease progression 
or   mortality. Similarly, a small study examining the effect 
of coenzyme Q10 produced interesting preliminary data 
for efficacy, but additional studies are needed to conclude a 
therapeutic benefit.13 Other pilot therapeutic interventional 
studies in the treatment of  PSP include lithium,14 rasagiline,15 
and valproic acid.16
This situation puts a high priority on clinical trials 
in PSP using novel drug candidates with a special focus 
on postural instability including the potential for disease 
modifying drugs. Clearly, neuroprotective drugs that can 
impact the underlying disease pathology would be of par-
ticular   importance. Tideglusib (Noscira, Madrid, Spain) is a 
GSK-3 inhibitor in Phase II clinical development for AD and 
PSP based on the hypothesis that preventing tau phosphoryla-
tion should benefit PSP patients. Another advanced product in 
PSP clinical trials, davunetide, takes an alternative approach 
to slow disease progression by stabilizing microtubules and 
presumably reducing tau pathology (Allon Therapeutics Inc, 
Vancouver, Canada). In the following sections, we review 
the nonclinical and clinical pharmacology of davunetide 
with particular attention paid to the rationale for testing 
davunetide in PSP in addition to providing data that support 
its use in other neurodegenerative disorders characterized by 
dysfunctional microtubules.
Davunetide: review of pharmacology, 
mode of action
Davunetide pharmacology
Davunetide (also referred to as NAPVSIPQ, NAP or AL-108) 
was originally described as a neuroprotective fragment of 
activity-dependent neuroprotective protein (ADNP).17 The 
parent protein was discovered as a glial-derived neuropro-
tectant and it has since been shown to be essential for fetal 
development18 due, at least in part, to its interaction with 
chromatin19 and its regulation of the expression of multiple 
neurogenesis and organogenesis-related genes.20 Davunetide, 
an eight amino acid fragment of ADNP, was found to be 
neuroprotective and is being developed as a therapeutic.
Davunetide has been extensively investigated and has 
demonstrated neuroprotection and improved cognitive perfor-
mance in multiple in vitro and in vivo preclinical studies.21–24 
In these experiments, davunetide has been shown to protect 
neurons and glial cells25 against a broad range of toxins 
including those relevant to AD and other neurodegenerative 
  disorders. The activity of davunetide also extends to promoting 
neuritic outgrowth26–30 and axon growth or branching.31 Such 
an effect of davunetide was also confirmed in vivo in a model 
of diabetes associated cognitive-dysfunction.25 With respect 
to in vivo testing of davunetide, activity has been seen in a 
wide range of disease models23,32,33 including, most recently, 
two models of chronic neurodegeneration that are relevant to 
tauopathies, such as PSP, and to PD, respectively (see below). 
Davunetide crosses the blood–brain barrier whether adminis-
tered intranasally or parenterally and demonstrates distribution 
throughout all areas of the brain34 suggesting that it will act 
upon compromised neurons regardless of their location.
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The potential impact of davunetide on the progressive 
degeneration mediated by tau was explored in transgenic 
mice expressing a mutated form of the human tau protein 
[P301S;K257T].33 Following daily davunetide treatment 
for approximately 5 months, drug treated animals showed 
statistically significant improvement, compared to controls, 
in the Morris water maze. Following an additional 5 months 
of treatment, the mice were examined for the presence of 
phosphorylated tau. The analysis showed that davunetide 
treatment reduced the levels of hyperphosphorylated tau 
compared to vehicle treated animals. These data, coupled 
with a decrease in staining of neurofibrillary tangles in these 
mice, provide support for davunetide’s ability to reduce tau 
pathology and improve cognitive performance. Such an effect 
provides support for the evaluation of davunetide in multiple 
neurodegenerative tauopathies.
The potential of davunetide to treat sporadic PD was 
investigated in mice overexpressing human wild-type 
α-synuclein under the Thy1 promoter (Thy1-aSyn) and 
littermate wild type controls. This mouse model accumu-
lates α-synuclein aggregates which are also seen in several 
neurodegenerative disorders (synucleinopathies), including 
PD.32 Two-month-old mice were treated daily with intranasal 
davunetide for 2 months and subjected to a variety of motor 
function tests at 4.5 months of age, and their brains were 
examined for proteinase K-resistant α-synuclein inclusions 
in the substantia nigra and olfactory bulb. Davunetide treated 
Thy1-aSyn mice showed improved motor performance 
(errors per step in the challenging beam traversal test) and a 
statistically significant reduction in α-synuclein inclusions 
in the substantia nigra. Since overexpression of α-synuclein 
negatively impacts microtubule-dependent transport,35,36 
these data suggest that compounds like davunetide that act 
on the microtubule cytoskeleton have potential for the treat-
ment of synucleinopathies.
Davunetide: mechanism of action
Cumulative evidence suggests that some neurodegenera-
tive diseases and psychiatric illnesses are associated with 
cytoskeletal alterations which result in a loss of synaptic 
structures and impaired synaptic transmission. As such, the 
neuronal cytoskeleton can be a target for drug therapy for 
these diseases and illnesses. Disruption of the cytoskeletal 
architecture and microtubule function has been associated 
with poor cognitive performance in animal models.37 Fur-
thermore, microtubule dependent transport is impaired in 
AD38 and axonopathies have been reported in different AD 
animal models,39 suggesting that perturbed   microtubule 
transport may underlie cognitive deficits observed in AD. 
The overlap between microtubule biochemistry and cell 
death/survival signaling in neurons is exemplified by work 
demonstrating the traditional role ascribed to tau as a 
microtubule stabilizing protein is incomplete, and that this 
protein in fact also acts as a scaffold or adaptor protein that 
is critical to signal transduction in dendritic spines.40 In this 
context, the cumulative data summarized here for davunetide 
shows that this molecule is acting on cellular pathways at 
the intersection of mechanisms critical to synaptic plasticity 
and neurotransmission.
Davunetide’s activity in cellular and animal models 
appears to be linked to maintenance of microtubule function 
and on inhibition of apoptosis.41,42 This effect on the micro-
tubular network is based, in particular, on observations that 
davunetide has protective effects against zinc intoxication in 
glial and neuronal cells that is accompanied by restoration of 
an intact microtubular cytoskeleton and apparent inhibition of 
toxic tubulin-zinc aggregate formation.29,43 Similarly, davu-
netide is able to promote repolymerization of microtubules 
after nocodazole treatment in primary neurons.44
The hypothesis that davunetide stabilizes microtubules is 
supported by the observation that davunetide increases the ratio 
of total tau to phosphorylated tau in vitro,45 an effect that is 
associated with stabilization of microtubules. Incubation with 
davunetide protected microtubules against the overexpression 
of katanin, a protein that severs microtubules playing a major 
role in sculpting microtubular structures.46 In this respect, davu-
netide was able to compensate for katanin-induced defective 
axonal branching in the presence of reduced tau   expression. 
In vivo confirmation comes from several animal models in 
which davunetide reduces the level of phosphorylated tau in 
models of AD,47,48 tauopathy33,49 and ADNP deficiency.50
A link between davunetide’s effects on microtubules 
and cell survival pathways is suggested by studies involv-
ing neuroprotection against toxic insults. For instance, 
the protective effect of davunetide in support of neuronal 
survival in the presence of compromised glia (as a conse-
quence of the glial prenatal ethanol exposure, PEE) has been 
described.31 Co-cultures of astrocytes from PEE animals 
with neurons from naïve animals resulted in a decreased 
number of viable neurons and of their synaptic connections 
compared to glial controls. Davunetide was able to rescue 
neurons from the effects of PEE-damaged astrocytes, with 
a concomitant increase in the phosphorylation of Akt, ERK 
MAPK and CREB. Blocking the activity of PI-3-kinase 
or ERK with small molecule inhibitors (wortmannin and 
PD 98059, respectively) prevented the neuroprotective 
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effects of   davunetide on cell viability and synaptic   connection 
  numbers.31 Similarly, in a mouse model of excitotoxic brain 
lesion mimicking brain damage associated with cerebral 
palsy, it was recently demonstrated that davunetide reduced 
the number of apoptotic neurons through activation of PI-3K/
Akt pathway in the cortical plate or both PI-3K/Akt and 
MAPK/MEK1 kinases in the white matter.51
Further, davunetide potentiated axon outgrowth in cere-
bellar granule neurons (CGNs) in serum-free conditions,52 
increasing the length of axons by about 70% relative to 
controls. Davunetide effects were blocked by an inhibitor of 
the Src family of kinases (SFKs), and inhibition of mitogen-
activated protein kinase kinase (MEK) but was unaffected 
by inhibition of protein kinase A (PKA) and cytochalasin D 
(an inhibitor of F-actin polymerization). Knockdown of 
Fyn kinase using siRNA abrogated the effect of davunetide 
on axons suggesting FynK and downstream mediators are 
required for davunetide’s activity. The ultimate downstream 
impact of such effects on intracellular signaling may be the 
modulation of gene expression as suggested by activation of 
CREB28 and polyADP-ribosylation.27
In conclusion, the data described in the preceding section 
indicate that davunetide affects multiple pathways that have 
direct translation to neurodegenerative disease at three levels 
(see Figure 1 for a schematic):
1.  Davunetide is able to modulate cytoskeletal structures 
within neurons and glia, at least in part due to a reduction 
in tau phosphorylation.
2.  Davunetide treatment reduces the phosphorylation of tau, 
in association with the modulation of intracellular signal-
ing cascades critical to cell survival, synaptic plasticity 
and microtubule stabilization.
3.  These cellular events ultimately result in maintenance of 
neurotransmission and cell viability which in turn pro-
vides a drug-dependent impact on disease progression.
Furthermore, preclinical pharmacology studies have 
shown that davunetide improves outcomes in models of dis-
eases where neurofibrillary tangles are not a major   hallmark. 
In such cases, we posit that the ability of davunetide to modu-
late microtubule-associated cell survival pathways accounts 
for the beneficial effects.
Davunetide: clinical development
Davunetide’s effect on human pharmacology was explored in 
a Phase II clinical study of amnestic mild cognitive impair-
ment (aMCI) patients.53,54 aMCI is a prodromal state of AD 
characterized by significant memory impairment but in which 
other cognitive functions remain relatively intact.55 The neuro-
pathology of aMCI which contributes to the memory impair-
ment appears to involve microtubule dysfunction resulting 
Activation of pro-death
signaling cascades
Neuronal microtubule dysfunction
Compromised
axonal transport
Tau phosphorylation
and aggregation
Loss of synaptic
structures 
RetrogradeA ntegrade
Axonal degeneration
Misfolding and accumulation of
toxic protein aggregates 
Reduced synaptic transmission
Neurodegeneration
Cell death
Reduced clearance
Reduced autophagy
Figure 1 Overview of neuronal microtubule dysfunction pathways leading to neurodegeneration.
Notes: Studies have demonstrated that disruption of microtubule structure and function has downstream consequences that ultimately lead to neurodegeneration and cell 
death. Among those effects initiated by microtubule dysfunction are the activation of cell death signaling cascades, axonal degeneration, dysregulation of axonal transport (both 
retrograde and anterograde transport) and the loss of synaptic structures. This diagram traces the downstream effects of those actions, including the critical events surrounding 
protein aggregation, that are responsible for the cell death and loss of synaptic transmission that represent critical events leading to neurodegeneration. Those pathways known to 
be impacted by the neuroprotective drug, davunetide, are shown in red. As described in the associated text, davunetide directly impacts pathways relevant to neurodegenerative 
disease at multiple levels in this schema. Studies have shown protection of microtubules against toxic insult, reduction in tau phosphorylation, reductions in aggregated proteins in 
animal models of disease, modulation of intracellular signaling cascades critical to cell survival, and markers of synaptic plasticity. These molecular events triggered by davunetide 
ultimately result in maintenance of neurotransmission and cell viability which in turn are manifested as a drug-dependent impact on disease progression.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
88
Gold et alNeuropsychiatric Disease and Treatment 2012:8
in neurofibrillary tangles composed of tau.55–57 Davunetide 
  consistently improves microtubule structure and function lead-
ing to a reduction in tau pathology in a variety of cell-based 
and animal models. Therefore, the hypothesis is davunetide 
can improve cognitive performance in aMCI patients.
A double blind, placebo-controlled study randomized 
144 subjects into three groups, placebo, 5 mg daily and 
15 mg twice daily for 12 weeks of treatment. Davunetide 
was generally safe and well-tolerated with an equal percent 
(approximately 50%) of adverse events reported by placebo 
subjects and davunetide-treated subjects. A slightly higher 
incidence of headache and nasopharyngeal adverse events 
was reported by davunetide-treated subjects compared to 
placebo (13% versus 6% for headache and 8%–9% versus 
2% for nasopharyngitis); however the total number was small 
and the severity was mild-to-moderate. Five cognitive tests 
were administered throughout the study (digit span, delayed-
match-to-sample, spatial working memory, paired associates 
learning, and One-Touch Stockings of Cambridge; Cambridge 
Cognition Ltd, UK). Davunetide 15 mg twice daily had a 
statistically significant impact on two measures, namely digit 
span and delayed-match-to-sample, tests of verbal recall and 
visual working memory, respectively. These exploratory data 
from the aMCI study serve as proof-of-principle and support 
the preclinical mechanism of action postulated for davunetide. 
While davunetide has also shown activity in an exploratory 
trial in cognitive impairment in schizophrenia,58 the data in 
aMCI provide the most relevant translation to PSP.
The opportunity to treat PSP, given its neuropathology, 
with davunetide follows from the clinical confirmation of 
activity obtained in the aMCI study. Since the distribution of 
tau pathology in the brain of PSP patients correlates well with 
the clinical presentation of symptoms, a reduction of the tau 
burden should translate into a reduced rate of progression in 
the clinical outcome measures. A pivotal Phase II/III study 
of PSP patients opened for enrollment in the fourth quarter 
of 2010 under a Special Protocol Assessment granted by the 
United States Food and Drug Administration. The placebo-
controlled study enrolled approximately 300 patients from 
the USA, Canada, Australia, Germany, France and the United 
Kingdom. Subjects in the study will be treated with placebo 
or davunetide 30 mg twice daily for 1 year. Results from the 
study are anticipated at the end of 2012.
Challenges and opportunities  
for clinical trials in PSP
The relationship between tau, PSP and AD59 provides drug 
developers with strong translational rationale to explore 
  tau-directed approaches, with some of these programs either 
in clinical development or close to entering that stage. PSP 
has emerged as an attractive clinical trial population for three 
main reasons: (1) it is a debilitating and life-threatening dis-
ease for which there is a desire to develop effective treatment 
options that currently do not exist; (2) from a scientific point 
of view, it serves to prove whether a tau-directed therapy can 
affect a primary neurodegenerative disease, thereby reducing 
the risk of failure in a related condition, namely AD; and (3) it 
is a rare disease that qualifies as an orphan indication thereby 
providing certain commercial incentives and allows sponsors 
to pursue development with more limited resources.
With this background, it is necessary to consider some key 
factors that impact the quality of clinical trials in PSP. Issues 
that are often particularly challenging when working in rare 
diseases in general are: (1) a well-defined patient   population; 
(2) validated and appropriate outcome   instruments; and 
(3) an intervention with a clear pharmacological rationale 
and data to support further testing. In the context of PSP, 
these three factors are interrelated and present substantial 
challenges in the design, execution and interpretation of 
results from a targeted clinical study. The following discus-
sion deals with these issues in turn, and describes how they 
can be overcome.
For clinical trials, and especially for a disease modify-
ing compound, the optimal study population is both homo-
geneous and at very early stages of the disease. Currently 
used diagnostic criteria2 have high levels of sensitivity and 
specificity for PSP compared to pathological diagnosis. 
However, because PSP may present with features of PD 
or other tauopathies, many patients are initially diagnosed 
with PD and only after they have failed treatment trials 
with dopaminergic compounds does their PSP diagnosis 
becomes apparent.60 While there are putative cerebrospinal 
fluid (CSF)61 and imaging biomarkers,62–64 a consequence 
of atypical or overlapping presentations is that many PSP 
patients are misdiagnosed at the earliest stages of the dis-
ease. Other potential pitfalls have included: (a) including 
subjects with putative PSP even if not all inclusion/exclu-
sion criteria are met; (b) starting or adjusting dopaminer-
gic medications in order to ensure that a patient is indeed 
non-responsive to dopaminergic medications and requiring 
subjects to undergo a prolonged stabilization period; (c) 
subjects with presentations that overlap CBD/FTD (fronto-
temporal dementia) requiring further evaluations; and (d) 
the lack of a validated biomarker precluding a population 
“  enrichment” strategy or a pharmacodynamic outcome 
instead of a   clinical outcome.
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In the Allon-sponsored study evaluating davunetide in 
PSP, several study design features were incorporated to help 
enroll as homogeneous a PSP population as possible. Firstly, 
the inclusion/exclusion criteria used were derived from sev-
eral long-term clinical trials in PSP where the sensitivity and 
specificity of diagnostic criteria were established. The current 
criteria emphasized the classic Richardson presentation65 to 
enhance homogeneity. Secondly, the investigators selected 
for this study were all PSP experts and intimately familiar 
with the diagnostic criteria, natural history and management 
of PSP as well as outcome instruments commonly used with 
these patients. In cases where the diagnosis was ambiguous, 
the study medical monitor (specialized in movement disor-
ders), the coordinating investigator and members of the study 
steering committee were available to discuss a given case with 
an investigator and reach a consensus about diagnosis and 
lastly the sponsor did not grant protocol exemptions based 
on diagnostic uncertainty.
With respect to the selection of outcome instruments, 
clinical trials often adopt scales or instruments developed for 
the diagnosis or staging of a disease as outcome instruments 
for interventional studies. This practice, while apparently 
driven by common sense, does not deal with the fact that 
the psychometric properties of an instrument designed for 
staging a disease may not be appropriate for use in detecting 
a response to intervention.66 Issues such as floor or ceiling 
effects are problematic in interventional studies. Accurate and 
precise data on rate of progression are critical when design-
ing studies aimed at disease modification; however, scales 
initially designed for staging are not ideal for determining 
rates of progression. A clear example of this issue is the rate of 
progression seen on the Alzheimer’s disease sssessment scale-
cognitive subscale (ADAS-Cog) in AD when compared to 
baseline severity. The instrument is insensitive to progression 
in either very mildly affected or severely affected patients. In 
the first case, the test may be too simple or fails to test affected 
domains whereas in the latter, the subject is so impaired that 
they cannot reliably be tested. The net effect is that the scale 
is sensitive to change in a relatively narrow band of severity. 
This is clearly a problem when one wants to test the effect 
of a disease modifying compound in subjects at the earliest 
possible stages of the clinical syndrome. The situation in PSP 
has evolved significantly from the use of PD-derived instru-
ments67 to the use of time-to-event outcomes2 (ie, survival, 
inability to walk or inability to stand) to validated composite 
scales such as the PSP rating scale (PSPRS) derived from 
longitudinal observational4 or interventional cohorts.68 Most 
of the currently used outcome instruments appear to have 
acceptable psychometric   properties (ie, inter-, intrarater [by 
the same rater or in between two raters assessing clinical 
phenotypes] reliability, stability etc); however, these tradi-
tional metrics are insufficient to characterize an outcome 
instrument for interventional clinical trials and calls for the 
use of more appropriate analyses such as item response or 
Rasch analyses.
These potential issues have been addressed in the assess-
ment of davunetide in PSP through the exclusion of patients 
with severe PSP that might have introduced overt floor effects, 
exclusion of subjects with dementia to reduce the impact of 
cognitive impairment on subject-reported outcomes and the 
implementation of a strict standardized training program for 
PSPRS raters. In addition, demographic and PSPRS data at 
baseline were compared to data from previous interventional 
studies or longitudinal cohorts using the PSPRS to determine 
whether substantial differences were apparent.
Lastly, the choice of compound to be taken into clinical 
trials is also a critical factor in the rationale for, and design of, 
a clinical trial. The most obvious gap in this area is the lack 
of validated models of PSP or other sporadic tauopathies and 
the resultant dependence on transgenic models. Drawing from 
the lessons learned in the AD arena, it appears that transgenic 
models, while useful as a way to validate the pharmacology of 
a given compound, should be used with a clear understanding 
of their limitations. In the absence of validated models, and an 
incomplete understanding of the pathophysiological cascade 
underlying sporadic PSP, a pragmatic approach is to target 
the salient pathological features in PSP using a variety of 
different models in order to determine whether the compound 
has consistently neuroprotective effects at concentrations that 
are achievable in the human brain. The clinical development 
of davunetide has encompassed elements of both strategies22 
using transgenic models directed at tau as well as a broad 
range of other models; all of which have consistently yielded 
evidence of a neuroprotective effect. Early clinical experience 
with davunetide in aMCI subjects provided evidence of excel-
lent safety, tolerability, and signs of efficacy.
Patients with PSP mostly live at home,69 and relatives 
are often the only caregivers. While both patients and rela-
tives frequently seek medical treatment, their willingness 
to participate in clinical trials has been surprisingly low 
historically.69 In studies requiring a complex therapeutic 
regimen, ensuring patient compliance is critically important; 
therefore, ensuring the cooperation of a reliable caregiver, 
such as a relative or a nursing-home employee, to accom-
pany patients to all study visits is mandatory. Individuals 
who want to participate in clinical trials must be fully aware 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
90
Gold et alNeuropsychiatric Disease and Treatment 2012:8
of the purpose, procedures, and possible benefits of the 
study.70 Study staff must provide sufficient time to allow for 
regular breaks and the transitions between different study 
investigations very carefully given the hypokinetic and 
bradyphrenic nature of PSP patients. If a study has included 
a large number of procedures it might be useful to perform 
them on two days, especially since cognitive tests may be 
flawed due to fatigue.
Conclusion
This review lays out some of the challenges encountered in 
interventional trials in PSP and the experience of recruiting the 
trial for the assessment of davunetide’s efficacy in PSP. This 
and previous clinical studies, demonstrate that the operational 
issues are tractable. In general, patients with PSP and their rela-
tives or caregivers strongly adhere to the tasks associated with 
clinical trial protocols. They are committed and do their best to 
perform well throughout their study. They are reliable partners 
in clinical trials since their ultimate hope is to assist in finding 
a drug that will ameliorate the symptoms of the disease and 
possibly even modify disease progression. As more experience 
has been gathered and novel treatment options have appeared, 
the understanding of operational issues in PSP trials has led to 
better trial methodology and provides a basis on which to test 
novel pharmacologic treatments such as davunetide. These 
advances, coupled with the support of key opinion leaders 
and advocacy groups, have been important in enrollment in 
the davunetide study being completed ahead of schedule sug-
gesting an eagerness for robust studies that have the potential 
to bring therapies to patients as quickly as possible.
Since no therapy exists to slow disease progression in 
PSP, there is an urgent need to identify compounds and to 
evaluate their potential in clinical studies. The pharmacologi-
cal profile of davunetide suggests that this compound may 
be effective in slowing down the neurodegenerative process 
observed in PSP and it is therefore important to study this 
drug in PSP patients.
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